Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 9/20 | 0.77 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288920 | 1.00 | CAPN1 (0.77) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1613008 | 1.00 | CAPN1 (0.77) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL289303 | 0.96 | CAPN1 (0.72) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1612451 | 0.96 | CAPN1 (0.72) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1611219 | 0.96 | CAPN1 (0.72) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL289125 | 0.95 | CAPN1 (0.71) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1612510 | 0.95 | CAPN1 (0.71) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL1612978 | 0.95 | CAPN1 (0.71) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL289012 | 0.92 | CAPN1 (0.77) | CAPN1ITGB1ITGA4P2RX7 | |
| SCHEMBL288801 | 0.92 | CAPN1 (0.77) | CAPN1ITGB1ITGA4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427429-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-15 | — | — | EP | claimed |
| US-8236798-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-08-07 | — | — | US | claimed |
| EP-4682264-A1 | ASSAY SYSTEM FOR DEVELOPING HONEYBEE ANTIVIRAL AGENT USING INHIBITION OF VIRUS-DERIVED PROTEASE AS INDICATOR | Toyama Prefectural University (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-20230190701-A1 | Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same | THE US GOV AS REPRESENTED (US) | 2023-06-22 | — | — | US | disclosed |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2022026894-A1 | COMPOUNDS FOR TREATING TAUOPATHIES AND RESTLESS LEG SYNDROME AND METHODS OF USING AND SCREENING FOR SAME | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220031653-A1 | Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-02-03 | — | — | US | disclosed |
| US-20210113560-A1 | METHOD OF TREATING FIBROTIC DISEASE | BLADE THERAPEUTICS INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| EP-2427429-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-9527811-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| US-9018206-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-06-13 | — | — | US | disclosed |
| US-8283363-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT LABORATORIES (US) | 2012-10-09 | — | — | US | disclosed |
| US-8236798-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-08-07 | — | — | US | disclosed |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885ITGB1 3429/4885ITGA4 3989/4885 |
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885ITGB1 4712/4885ITGA4 4800/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CAPN1 4/4885ITGB1 2849/4885ITGA4 3456/4885 |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885ITGB1 4712/4885ITGA4 4800/4885 |
| US-20230190701-A1 | Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same | PTPRR, PTPRS, PPP6C | CAPN1 2615/4885ITGB1 4812/4885ITGA4 4824/4885 |
| US-20220031653-A1 | Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same | PTPRR, PTPRS, PPP6C | CAPN1 2615/4885ITGB1 4812/4885ITGA4 4824/4885 |
| US-20210113560-A1 | METHOD OF TREATING FIBROTIC DISEASE | CAPN9, CAPNS1, CAPN1 | CAPN1 3/4885ITGB1 921/4885ITGA4 1952/4885 |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885ITGB1 4712/4885ITGA4 4800/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885ITGB1 3429/4885ITGA4 3989/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885ITGB1 3429/4885ITGA4 3989/4885 |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885ITGB1 4712/4885ITGA4 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.